Litigation Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2015)
✉ Email this page to a colleague
AbbVie Inc. v. Hetero USA Inc. (D. Del. 2015)
| Docket | ⤷ Start Trial | Date Filed | 2015-10-02 |
| Court | District Court, D. Delaware | Date Terminated | 2015-10-27 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 6,037,157; 6,703,403; 7,148,359; 7,364,752; 8,025,899; 8,268,349; 8,309,613; 8,377,952; 8,399,015; 8,470,347; 8,691,878 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AbbVie Inc. v. Hetero USA Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-10-02 | External link to document | |||
| 2015-10-02 | 1 | civil action for patent infringement of: (1) United States Patent Number 6,037,157 B1 as amended by … known as Number 6,037,157 C1 (together “the ’157 Patent”); (2) United States Patent Number 6,703,403…Certificate, which amended the ’157 Patent as United States Patent Number 6,037,157 C1. AbbVie Inc. is the owner…B2 (“the ’403 Patent”); (3) United States Patent Number 7,148,359 B2 (“the ’359 Patent”); (4) United …together “the ’752 Patent”); (5) United States Patent Number 8,025,899 (“the ’899 Patent”); (6) United States | External link to document | |
| 2015-10-02 | 7 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,037,157; 6,703,403; 7,148,359…2015 27 October 2015 1:15-cv-00889 830 Patent None District Court, D. Delaware | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
